Apart from the above, Aditya Birla Sun Life, Ajanta Pharma, Arvind Ltd, Bhageria Industries, Car Trade Tech, Federal Bank, Ideaforge, Indian Bank, Motilal Oswal, Northern Arc Capital, Pfizer and a few others will also declare their results.
Airtel Q2 expectations
Bharti Airtel is expected to report a strong set of numbers in the September ended quarter with triple-digit net profit growth over the corresponding quarter of the previous financial year. Industry leading ARPU and support from other business segments could augur well for the company on the revenue front.The profit after tax (PAT) is estimated in the range of Rs 4,570 crore and Rs 5,217 crore in Q2FY25, which translates into an year-on-year growth of 103-254%.The earnings estimates have been given by Axis Securities, Kotak Institutional Equities, Nuvama Institutional Equities, JM Financial and Centrum Broking.
Bharti Airtel is expected to report its revenue numbers between Rs 40,822 crore and Rs 41,591 crore which is a 10-12% YoY growth.
Centrum remains most conservative among the above brokerages on the revenue and PAT growth numbers while Kotak remains most bullish.
Sun Pharma Q2 expectations
Pharma major Sun Pharma is expected to report healthy revenue growth during the second quarter, driven by the domestic business with favourable seasonality and growing volumes.
Revenue from operations is likely to jump 10% year-on-year, according to an average estimate of four brokerages. Meanwhile, net profit for the quarter is seen rising up to 25% year-on-year.
Analysts are building in $482 million US sales in 2QFY25, primarily due to higher specialty sales, tad higher gRevlimid sales, as well as continued ramp-up in gPentasa supplies from Mohali.
Gross margins are likely to improve on a sequential basis, while EBITDA margins may drop due to higher research and development (R&D) spending.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)